MMP-9-IN-1

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

MMP-9-IN-1 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Definition

  ChEBI: MMP-9-IN-1 is a secondary carboxamide resulting from the formal condensation of the carboxy group of [(4-oxo-6-propyl-1,4-dihydropyrimidin-2-yl)sulfanyl]acetic acid with the amino group of 4-(difluoromethoxy)aniline. It is a specific matrix metalloproteinase-9 (MMP-9) inhibitor. It has a role as an EC 3.4.24.35 (gelatinase B) inhibitor and an antineoplastic agent. It is an organofluorine compound, an aromatic compound, a pyrimidone, an organic sulfide and a secondary carboxamide.

• Biologische Aktivität

  MMP-9-IN-1 (OUN87710) is a specific inhibitor of matrix metalloproteinase-9 (MMP-9). MMP-9-IN-1 selectively targets the heme (PEX) domain of MMP-9 with a Kd of 2.1 μM.

• in vivo

  MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor.
  MMP-9-IN-1 inhibits cancer cell metastasis in vivo.

  Animal Model:	4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor
  Dosage:	20 mg/kg
  Administration:	Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
  Result:	Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.

• target

  Target	Value
  MMP-9 (Cell-free assay)	2.1 μM(Kd)

MMP-9-IN-1 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(28)Suppliers